STERIPACK ANNOUNCES BUYOUT BY INFLEXION

LAKELAND, Fla., July 6, 2022 /PRNewswire/ -- SteriPack Group ("SteriPack"), a leading global contract manufacturer serving the medical device, pharmaceutical, and diagnostic markets, announces Inflexion Private Equity Partners, a leading UK-based private equity firm, has led the buyout of SteriPack. This strategic partnership positions SteriPack for accelerated growth, geographical expansion, and an enhanced service offering to better support current and future customers.


SteriPack provides holistic and integrated product life-cycle management services commencing with award winning product design & development, human factors research & engineering, regulatory, QA, DFM, manufacturing, sterilization, and supply chain management. The company employs over 650 people from its locations in Ireland, Poland, Malaysia, and the US, and has over 100 clients.


The funding from Inflexion will support the business to continue to scale globally as it benefits from strong market growth and further international expansion opportunities. SteriPack is also well placed to undertake further acquisitions with the support of Inflexion.


Andrew McLean, CEO of SteriPack, said, "We're very proud of our strong growth record and are keen to build on it to take SteriPack even further as we become even more valued partners to our customers through expansion of our capabilities and geographic footprint. Inflexion's presence in our core markets of Europe, Asia and the US as well as its extensive M&A experience make it the ideal partner to support our future international growth."


Flor Kassai, Partner and Head of Inflexion's Buyout Fund, commented, "SteriPack is clearly an extremely successful niche market player whose ongoing focus on high-quality innovation has earned it an impressive and loyal client roster. We are incredibly excited to bring our experience to bear to help management accelerate its growth further across the globe."